173 related articles for article (PubMed ID: 37208566)
1. Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.
Gudmundsdottir H; Habermann EB; Vierkant RA; Starlinger P; Thiels CA; Warner SG; Smoot RL; Truty MJ; Kendrick ML; Halfdanarson TR; Nagorney DM; Cleary SP
Ann Surg Oncol; 2023 Aug; 30(8):4840-4851. PubMed ID: 37208566
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
3. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
[TBL] [Abstract][Full Text] [Related]
4. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.
Lang H; Schlitt HJ; Schmidt H; Flemming P; Nashan B; Scheumann GF; Oldhafer KJ; Manns MP; Raab R
Langenbecks Arch Surg; 1999 Aug; 384(4):370-7. PubMed ID: 10473858
[TBL] [Abstract][Full Text] [Related]
5. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
7. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
8. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
9. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
10. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
11. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
12. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study.
Elias D; Lasser P; Ducreux M; Duvillard P; Ouellet JF; Dromain C; Schlumberger M; Pocard M; Boige V; Miquel C; Baudin E
Surgery; 2003 Apr; 133(4):375-82. PubMed ID: 12717354
[TBL] [Abstract][Full Text] [Related]
13. Synchronous resection of primary and liver metastases for neuroendocrine tumors.
Gaujoux S; Gonen M; Tang L; Klimstra D; Brennan MF; D'Angelica M; Dematteo R; Allen PJ; Jarnagin W; Fong Y
Ann Surg Oncol; 2012 Dec; 19(13):4270-7. PubMed ID: 22752376
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.
Mazzaglia PJ; Berber E; Milas M; Siperstein AE
Surgery; 2007 Jul; 142(1):10-9. PubMed ID: 17629995
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy.
Ammann M; Gudmundsdottir H; Hackl H; Antwi SKA; Santol J; Habermann EB; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Nagorney DM; Cleary SP; Halfdanarson TR; Starlinger PP
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38717544
[TBL] [Abstract][Full Text] [Related]
16. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
[TBL] [Abstract][Full Text] [Related]
17. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.
Wonn SM; Limbach KE; Pommier SJ; Ratzlaff AN; Leon EJ; McCully BH; Pommier RF
Surgery; 2021 Jan; 169(1):168-174. PubMed ID: 32473829
[TBL] [Abstract][Full Text] [Related]
19. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma.
Andreou A; Knitter S; Klein F; Malinka T; Schmelzle M; Struecker B; Schmuck RB; Noltsch AR; Lee D; Pelzer U; Denecke T; Pratschke J; Bahra M
Surg Oncol; 2018 Dec; 27(4):688-694. PubMed ID: 30449494
[TBL] [Abstract][Full Text] [Related]
20. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group.
Zhang XF; Wu Z; Cloyd J; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
Surgery; 2019 Mar; 165(3):548-556. PubMed ID: 30278986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
